Daily-life measurement enters psilocybin research for depression
Psilocybin has drawn attention for depression treatment, but clinical response remains uneven. Some people improve substantially after dosing, while others experience limited benefit or distressing effects that can shadow the entire experience. The Dial-In study is designed to move beyond the usual before-and-after clinic visit model and observe what actually happens in daily life before and after a 25 mg psilocybin dose.
This matters because symptom scores collected at a few fixed time points can miss the lived texture of change. A patient may look better on a depression scale at week 2, yet still be withdrawing socially, ruminating intensely, or struggling with the emotional residue of a difficult dosing session. By embedding intensive ambulatory monitoring inside a clinical trial of psilocybin for major depressive disorder, investigators are trying to map the path from dose day to everyday functioning with far more granularity than standard trial designs allow.
A multimethod design built to capture behavior outside the clinic
Dial-In is a prospective, observational, longitudinal study nested within a clinical trial that will administer 25 mg of psilocybin to up to 141 adults with major depressive disorder. The observational layer is not a separate experiment; it is stitched directly onto the treatment trial so researchers can track real-world patterns alongside the dosing experience itself.
The assessment strategy is unusually dense. Ecological momentary assessment, or EMA, will sample affect and behavior repeatedly over 14 days before dosing and 14 days after dosing. Participants will also complete voice diaries during those same periods, adding a more narrative and potentially less constrained record of daily reflections. On top of that, passive audio sampling through the Electronically Activated Recorder, or EAR, will collect three four-day windows of everyday sound and conversation, offering a way to characterize social interactions without relying entirely on memory or retrospective reporting.
That combination should help investigators identify whether change emerges as a steady slope, a sudden shift, or a jagged sequence of gains and losses. In depression research, those distinctions are rarely visible when assessments are separated by weeks or months. A person may show a rapid lift in positive affect, followed by a quieter period marked by increased rigidity or interpersonal strain. Another may experience a difficult dosing day, then stabilize with improved psychological flexibility and better social engagement. The study is built to detect those diverging trajectories rather than compress them into a single endpoint.
Sudden gains, sudden losses, and the social context of recovery
The core analytic question is straightforward but clinically important: which everyday processes distinguish better from worse outcomes after psilocybin? The study will examine whether affective sudden gains and losses, social support, interpersonal conflict, conversational focus, reflection, and rigidity predict differential response. Each of those variables speaks to a different layer of post-dose adaptation.
Affective sudden gains may reflect fast relief from hopelessness or emotional constriction. Sudden losses may point to destabilization, lingering dysphoria, or a mismatch between the acute psychedelic experience and the person’s ability to integrate it. Social support can buffer distress and help translate insight into sustained change, while interpersonal conflict may erode those gains or expose vulnerabilities that a clinic visit never captures. Conversational focus and patterns of reflection may be especially relevant in depression, where self-focused thought can slide from adaptive processing into ruminative loops. Rigidity, by contrast, may mark a cognitive style that resists the openness and psychological flexibility often thought to accompany therapeutic response.
One sentence captures the study’s practical value: adverse experiences may not be the end of the story, but they can redirect the story sharply.
Challenging dosing experiences will be examined in real-world context
The protocol gives special attention to challenging dosing experiences. Some patients undergo psychedelic sessions that are emotionally difficult, frightening, or disorganizing, and those experiences may be followed by either clinical improvement or worsening. Rather than treating such events as isolated complications, Dial-In will test whether the everyday factors measured around dosing moderate the association between challenging experiences and later outcomes.
This is where the design becomes especially useful for clinicians. If a difficult session is followed by worsening depression only in participants with low support, high interpersonal conflict, or persistent rigidity, then post-dose follow-up may need to be tailored very differently. If the same difficult session is associated with improvement when participants show rapid reflective processing and stronger social engagement, then integration may be doing some of the therapeutic heavy lifting. The study does not assume that a difficult psychedelic experience is uniformly harmful or uniformly meaningful. It asks what surrounds the experience, how people process it, and whether the surrounding behavioral pattern changes the clinical result.
Outcomes tracked through eight weeks after dosing
The main outcomes extend through eight weeks after the psilocybin dose and include depressive symptoms, psychological well-being, and psychedelic-related adverse effects. That follow-up window is long enough to capture more than the immediate aftermath of the session but still short enough to focus on the period when early response and integration are likely to matter most.
The study’s emphasis on both benefit and harm is clinically important. Depression trials that focus only on symptom reduction can miss the full range of post-treatment experience, especially when an intervention produces powerful acute effects that may not translate neatly into durable recovery. By following both well-being and adverse effects, the protocol acknowledges that improvement and distress can coexist, and that the relationship between them may depend on daily-life behavior after the dose.
Ethics, oversight, and the limits of a protocol-stage study
The project received approval from the WCG Institutional Review Board, with Emory University relying on WCG as the reviewing board. All participants will provide written informed consent. Findings are slated for peer-reviewed publication and scientific presentation.
Because this is a protocol, not a results paper, it does not yet answer whether the monitoring strategy will predict outcomes or reveal a reliable behavioral signature of response. It also does not establish whether any observed associations will be strong enough to guide treatment decisions in routine practice. The sample will be limited to adults enrolled in a psilocybin depression trial, and the observational structure means the study can identify links between daily-life processes and outcomes, not prove causation.
Even so, the design addresses one of the central problems in psychedelic psychiatry: the gap between an intense dosing session and the ordinary life in which recovery must either hold or collapse. If psilocybin changes depression through shifts in affect, reflection, social connection, and behavioral flexibility, those changes are likely to appear first in the rhythms of daily life. Dial-In is built to catch them there.